141.93
-1.44 (-1.00%)
| Previous Close | 143.37 |
| Open | 140.99 |
| Volume | 818,706 |
| Avg. Volume (3M) | 850,900 |
| Market Cap | 4,850,361,344 |
| Price / Earnings (TTM) | 55.88 |
| Price / Earnings (Forward) | 58.82 |
| Price / Sales | 9.74 |
| Price / Book | 13.56 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | 10.03% |
| Operating Margin (TTM) | 19.12% |
| Diluted EPS (TTM) | 1.42 |
| Quarterly Revenue Growth (YOY) | 48.20% |
| Quarterly Earnings Growth (YOY) | 110.60% |
| Total Debt/Equity (MRQ) | 194.67% |
| Current Ratio (MRQ) | 9.10 |
| Operating Cash Flow (TTM) | 49.38 M |
| Levered Free Cash Flow (TTM) | -84.81 M |
| Return on Assets (TTM) | 4.21% |
| Return on Equity (TTM) | 22.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | TransMedics Group, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 121.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 166.00 (Needham, 16.96%) | Buy |
| Median | 148.00 (4.28%) | |
| Low | 135.00 (Morgan Stanley, -4.88%) | Hold |
| Average | 149.67 (5.45%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 133.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 17 Dec 2025 | 148.00 (4.28%) | Buy | 121.93 |
| Needham | 08 Dec 2025 | 166.00 (16.96%) | Buy | 136.60 |
| Morgan Stanley | 02 Dec 2025 | 135.00 (-4.88%) | Hold | 141.77 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts |
| 30 Dec 2025 | Announcement | TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference |
| 24 Dec 2025 | Announcement | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 18 Nov 2025 | Announcement | TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |